Boston 1型人工角膜术后青光眼发生与进展的系统综述与荟萃分析
术后任何形式青光眼事件的合并发生率为25.6%,新发青光眼为31.1%,原有青光眼进展为37.7%。
要点
- KPro术后任何形式青光眼事件合并发生率为25.6%(95%CI 18.1-34.8%)。
- 新发青光眼合并发生率为31.1%,原有青光眼进展率为37.7%。
- 证据确定性极低,需围手术期密切监测并标准化诊断标准。
核心结论
- 青光眼是KPro植入术后临床重要并发症,约四分之一至三分之一术眼术后发生。
- 尽管证据确定性极低,结果强调围手术期密切监测和标准化诊断方法的必要性。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL自建库至2025年6月。
- 采用随机效应模型进行荟萃分析,使用Joanna Briggs Institute工具评估偏倚风险,GRADE评估证据确定性。
主要发现
- 术后任何形式青光眼事件的合并发生率为25.6%(95%CI 18.1-34.8%,I²=87.3%),发生率为0.09事件/眼年(95%CI 0.07-0.13,I²=91.6%)。
- 明确报告新发青光眼的研究中,合并发生率为31.1%(95%CI 20.6-43.9%,I²=70.6%)。
- 原有青光眼进展发生在37.7%的眼中(95%CI 17.9-62.6%,I²=85.7%)。
- 未确诊青光眼的高眼压见于17.1%的眼中(95%CI 5.6-41.9%,I²=71.3%)。
关键数值与推荐
- 术前原有青光眼占45.9%的眼。
- 平均患者年龄54.5岁(±8.9)。
临床怎么用
- KPro植入术前应评估青光眼状态,术后需警惕青光眼发生与进展。
- 围手术期应加强眼压监测,并推动标准化青光眼诊断定义。
局限性
- 研究间存在显著异质性,源于结局定义、KPro适应证和报告习惯的差异。
- 证据确定性极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: Boston Type 1 Keratoprosthesis (KPro) implantation is an established surgery for severe corneal blindness when traditional keratoplasty is not feasible. This systematic review and meta-analysis aimed to quantify the incidence and progression of glaucoma following KPro implantation. CLINICAL RELEVANCE: Despite advances in device design and postoperative management, glaucoma remains a sight-threatening complication. Accurate estimates of glaucoma incidence and progression can inform treatment decisions and enhance long-term visual outcomes in this high-risk population. METHODS: MEDLINE, Embase, and CENTRAL were systematically searched from inception to June 2025. Two independent reviewers performed title/abstract screening, full-text screening, data extraction, and risk-of-bias assessment, with discrepancies resolved through discussion with a third reviewer. Studies reporting glaucoma-related outcomes following KPro implantation were included. Random-effects meta-analyses were performed to estimate pooled incidences of postoperative glaucoma. Risk of bias was assessed using Joanna Briggs Institute tools, and certainty of evidence was evaluated using GRADE. This review was prospectively registered on PROSPERO (ID: CRD420251036643). RESULTS: Twenty-three studies met inclusion criteria, encompassing 1,482 eyes with a mean follow-up of 39.4 months (±14.4). The mean patient age was 54.5 years (±8.9). Pre-existing glaucoma affected 45.9% of eyes. Overall, the pooled incidence of any form of postoperative glaucoma events was 25.6% (95% CI: 18.1-34.8%, I² = 87.3%) and an incidence rate of 0.09 events per eye-year (95% CI: 0.07-0.13; I² = 91.6%). Among studies explicitly reporting de novo glaucoma, the pooled incidence was 31.1% (95% CI: 20.6-43.9%, I² = 70.6%), while progression of pre-existing glaucoma occurred in 37.7% of eyes (95% CI: 17.9-62.6%, I² = 85.7%). Ocular hypertension without diagnostic confirmation of glaucoma was observed in 17.1% of eyes (95% CI: 5.6-41.9%, I² = 71.3%). Significant heterogeneity was observed across studies, stemming from variability in outcome definitions, indication for KPro, and reporting practices. CONCLUSIONS: Glaucoma represents a clinically important complication following KPro implantation, affecting approximately one-quarter to one-third of eyes postoperatively. Although the certainty of evidence is very low due to heterogeneity and variability in diagnostic definitions, the results underscore the need for vigilant perioperative monitoring and standardized diagnostic approaches.
引用
- Abu Osba A, Sawires K, Bondok M, et al. Incidence and Progression of Glaucoma Following Boston Type 1 Keratoprosthesis: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 42167434. doi:10.1016/j.ajo.2026.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。